Calcium dobesilate monohydrate is a well-established vasoprotective agent that has gained significant importance in managing various vascular disorders worldwide. This synthetic compound has been the subject of extensive research and clinical application over the past decades, demonstrating promising results in treating conditions associated with microvascular dysfunction.
This comprehensive review explores the various aspects of calcium dobesilate monohydrate, from its chemical properties to clinical applications and safety profile.
Introduction
Calcium dobesilate, chemically known as 2,5-dihydroxybenzene sulfonate calcium salt, is a synthetic drug widely used in the treatment of diabetic retinopathy and chronic venous insufficiency. Since its introduction to clinical practice, it has been prescribed in more than 60 countries across Europe, Latin America, Asia, and the Middle East. The compound exists in two primary forms: the free acid form (anhydrous) and the monohydrate form, with the latter being more commonly used in pharmaceutical preparations.
As a vasoprotective agent, calcium dobesilate works by improving microcirculation through multiple mechanisms, primarily by reducing capillary permeability and fragility, decreasing blood viscosity, and enhancing fluid removal through the lymphatic system. Its ability to address both the structural and functional aspects of vascular disorders has made it a valuable therapeutic option in various clinical settings where microvascular dysfunction plays a pathogenic role.
Chemical Structure
Calcium dobesilate monohydrate is the calcium salt of dobesilic acid (2,5-Dihydroxy Benzene Sulfonic acid) with one water molecule attached to the free acid form. Its chemical formula is C₁₂H₁₂CaO₁₁S₂, differentiating it from the anhydrous form which has the formula C₁₂H₁₀CaO₁₀S₂. Physically, it appears as a white hygroscopic powder with high solubility in water and alcohol, but is practically insoluble in dichloromethane and has poor solubility in isopropyl alcohol. When prepared as a 10% aqueous solution, calcium dobesilate monohydrate exhibits a pH range between 4.5 and 6.0.
The compound’s molecular weight is approximately 418.40 g/mol. Its chemical structure consists of two dobesilic acid molecules bound to a central calcium ion, with the addition of one water molecule in the monohydrate form. This structural arrangement contributes to its unique pharmacological properties and its ability to interact with biological systems involved in vascular integrity and blood flow regulation.
Calcium Dobesilate-Based Medicines List
Calcium dobesilate is marketed worldwide under various brand names, reflecting its global acceptance in therapeutic practice. Below are the top eight calcium dobesilate-based medications available in different markets:
- Doxium – Manufactured by OM Pharma, this is one of the oldest and most recognized brands, available primarily in Switzerland and many European countries, typically as 500 mg capsules.
- Dobesil – Produced by several manufacturers including Sun Pharmaceutical Industries and Incepta Pharmaceuticals, widely available in India and Bangladesh, offered in both 500 mg capsule and topical formulations.
- Dobimust – Manufactured by Mankind Pharma Ltd, primarily available in the Indian market as 500 mg capsules.
- Cabisyl – Produced by Rusan Pharma Ltd, available as 500 mg capsules and known for its presence in various international markets.
- Venosuf – Manufactured by Obsurge Biotech Ltd, marketed primarily in India and neighboring countries.
- Dovas – Produced by Sunways India Pvt Ltd, available as standard 500 mg formulations.
- Doberol – Manufactured by Lupin Ltd, a well-established pharmaceutical brand in the Indian market.
- Cadosil – Produced by UniMed UniHealth Pharmaceuticals Ltd, available in Bangladesh as both oral capsules and topical preparations, including combination formulations with lidocaine and dexamethasone for hemorrhoid treatment.
These medications are available in various forms including capsules, tablets, and topical preparations, catering to different therapeutic needs and administration preferences.
Mechanism of Action
Calcium dobesilate monohydrate exerts its therapeutic effects through multiple mechanisms that collectively improve microcirculation and vascular health. The primary mechanism involves the reduction of capillary permeability, which is achieved by stabilizing the basement membrane of blood vessels, particularly through its interaction with collagen chains.
This stabilization reinforces the overall integrity of the capillary wall and reduces leakage of fluid into surrounding tissues. Additionally, calcium dobesilate interacts with various biochemical mediators that regulate capillary permeability, leading to a further reduction in vascular leakage.
Beyond its effects on vascular permeability, calcium dobesilate decreases blood viscosity, especially at low shear rates relevant to venous flow, which improves blood circulation through affected vessels. Recent research has revealed that calcium dobesilate stimulates the production of nitric oxide (NO) in the endothelium, promoting vasodilation and potentially improving circulation in tissues affected by microangiopathy. The compound also demonstrates notable anti-platelet aggregation properties, which help prevent thrombus formation and maintain blood fluidity.
Furthermore, emerging evidence suggests that calcium dobesilate possesses anti-inflammatory properties, which may contribute to its therapeutic benefits in conditions like chronic venous insufficiency and hemorrhoids. By addressing multiple aspects of vascular dysfunction-structural integrity, blood rheology, endothelial function, and inflammation-calcium dobesilate offers a comprehensive approach to treating microvascular disorders.
Pharmacokinetics
Following oral administration, calcium dobesilate monohydrate demonstrates favorable pharmacokinetic properties that contribute to its clinical efficacy. The drug is well absorbed from the gastrointestinal tract after oral intake.
When administered as a 500 mg oral dose, blood levels of calcium dobesilate remain above 6 μg/ml between the third and tenth hour post-administration. Maximum plasma concentrations (Cmax) of approximately 8 μg/ml are typically reached about six hours after oral administration, with concentrations generally maintained for over 12 hours.
Studies have reported variable half-life (T1/2) values for calcium dobesilate, ranging from 3.7 to 9.4 hours depending on the study population and specific conditions. The pharmacokinetic profile is characterized by relatively low protein binding, with an unbound fraction (Funbound) of approximately 5%. This characteristic may contribute to its good tissue distribution and bioavailability at target sites.
Metabolism of calcium dobesilate is minimal, with less than 10% of the administered dose undergoing biotransformation. Elimination occurs primarily through renal excretion, with the drug being cleared from the circulation within 20 hours after administration, suggesting minimal risk of accumulation with standard dosing regimens.
The favorable pharmacokinetic profile of calcium dobesilate supports its convenient dosing schedule, typically 500-1500 mg daily divided into one to three doses, and contributes to its overall safety and efficacy in clinical practice.
Therapeutic Uses
| Condition | Mechanism | Dosage | Evidence Level |
|---|---|---|---|
| Diabetic Retinopathy | Reduces capillary leakage, improves blood-retinal barrier function, decreases retinal hemorrhages | 500-1000 mg daily for 2-6 months | High – Multiple randomized controlled trials |
| Chronic Venous Insufficiency | Reduces edema, improves venous tone, decreases capillary fragility | 500-1500 mg daily for 3-6 months | High – Well-established efficacy in placebo-controlled studies |
| Hemorrhoids (Piles) | Reduces inflammation, improves local circulation, strengthens vascular walls | 500-1000 mg daily oral; 4% topical preparation for external use | Moderate – Clinical studies support efficacy |
| Varicose Veins | Improves venous blood flow, reduces vascular leakage and edema | 500-1000 mg daily for 3-6 months | Moderate – Multiple clinical trials |
| Leg Ulcers | Enhances microcirculation, promotes healing | 500-1000 mg daily until healing occurs | Moderate – Clinical evidence supports use |
| Myocardial Ischemia (Experimental) | Improves lymphatic drainage, accelerates removal of degradation products | 100 mg/kg intravenous (animal studies) | Low – Primarily experimental evidence |
| Spider Veins | Strengthens blood vessel walls, reduces inflammation | 500 mg daily for 2-3 months | Low – Limited clinical evidence |
| Microangiopathies (Various) | Improves microcirculation and reduces capillary fragility | 500-1000 mg daily | Moderate – Various clinical studies |
Side Effects
Calcium dobesilate monohydrate is generally well-tolerated, with a favorable safety profile established through extensive clinical use and post-marketing surveillance reports spanning several decades. The incidence of adverse events associated with calcium dobesilate is relatively low, and most reported side effects are mild and transient in nature.
Gastrointestinal disturbances, including nausea, diarrhea, and vomiting, represent the most commonly reported adverse effects, occurring in approximately 12.5% of cases according to postmarketing surveillance data. These symptoms typically resolve spontaneously or with dose adjustment.
Skin reactions occur in about 8.2% of patients taking calcium dobesilate and may manifest as rashes or other dermatological symptoms. Fever has been reported in approximately 26% of adverse event cases, while arthralgias (joint pain) occur in about 4.3% of affected individuals. These reactions are generally self-limiting and rarely require discontinuation of therapy. One of the most serious, albeit extremely rare, adverse effects associated with calcium dobesilate is agranulocytosis, reported in about 4.3% of adverse event cases.
However, the estimated prevalence of agranulocytosis is extraordinarily low at approximately 0.32 cases per million treated patients-ten times less than the calculated prevalence in the general population. A comprehensive review concluded that most adverse events associated with calcium dobesilate are type B reactions (rare and unrelated to the drug’s pharmacological properties) and that the overall risk of adverse effects with calcium dobesilate at doses of 500-1500 mg/day is low and constant over time.
Drug Interactions
Calcium dobesilate monohydrate has demonstrated a remarkably clean drug interaction profile, which contributes to its safety when used in patients with multiple comorbidities who may be taking various medications concurrently. According to the available data, no specific drug interactions have been definitively established for calcium dobesilate. This favorable interaction profile makes it a particularly suitable option for elderly patients and those with complex medication regimens.
The only documented laboratory interaction is that calcium dobesilate may interfere with creatinine assays at therapeutic doses, potentially resulting in lower-than-actual values. This interference should be considered when interpreting renal function tests in patients taking calcium dobesilate, and healthcare providers should be informed about this potential interaction to avoid misinterpretation of laboratory results.
Despite the generally favorable interaction profile, it remains prudent for patients to inform their healthcare providers about all medications they are taking, including prescription drugs, over-the-counter medications, and dietary supplements, before initiating calcium dobesilate therapy.
This precautionary approach ensures comprehensive medication management and minimizes any potential for undocumented interactions. The absence of significant drug interactions contributes to the overall safety profile of calcium dobesilate and facilitates its integration into complex treatment regimens.
Safety Considerations
Several important safety considerations should be kept in mind when prescribing or taking calcium dobesilate monohydrate. The drug is contraindicated in patients with known hypersensitivity to calcium dobesilate or any component of the formulation.
In patients with severe renal insufficiency requiring dialysis, dosage adjustment is necessary, typically involving a reduction in the standard dose to account for decreased drug clearance. This precaution helps maintain therapeutic efficacy while minimizing the risk of adverse effects in this vulnerable population.
Regarding use during pregnancy, calcium dobesilate is classified as pregnancy category C, indicating that animal reproduction studies have shown adverse effects on the fetus, but there are no adequate and well-controlled studies in humans. Consequently, the drug should only be administered during pregnancy if the potential benefit justifies the potential risk to the fetus.
Studies have shown that calcium dobesilate enters maternal milk in very low quantities (approximately 0.4 μg/ml after intake of 3×500 mg). As a precautionary measure, either treatment with calcium dobesilate or breastfeeding should be discontinued during the treatment period.
Due to insufficient safety and efficacy data in pediatric populations, calcium dobesilate is not recommended for use in children. Patients with a history of blood disorders, particularly leukopenia or other hematological abnormalities, should be monitored closely when taking calcium dobesilate, given the extremely rare but serious risk of agranulocytosis.
Healthcare providers should advise patients to seek immediate medical attention if they develop signs of infection, such as fever, sore throat, or anogenital inflammation, which could potentially indicate hematological complications. Regular monitoring of blood counts may be prudent in high-risk patients or those on long-term therapy.
Regulatory Status
Calcium dobesilate monohydrate has achieved significant global regulatory acceptance, being available in more than 60 countries across Europe, Latin America, Asia, and the Middle East. The regulatory status varies by region, with different countries having specific approval frameworks for the compound.
In Switzerland, for example, calcium dobesilate is sold under the trade name Doxium by OM Pharma and is approved for the treatment of microangiopathies (particularly diabetic retinopathy), chronic venous insufficiency, and hemorrhoidal syndrome.
In India, calcium dobesilate received Food and Drug Administration (FDA) approval for generic manufacturing through Taj Pharmaceuticals in 2007, allowing for the production of various formulations including 500 mg calcium dobesilate monohydrate capsules and combination products. This approval facilitated broader access to the medication in various markets, including non-regulated regions such as the Middle East, Thailand, and Bangladesh.
The regulatory classification of calcium dobesilate typically falls under vasoprotective agents, with the Anatomical Therapeutic Chemical (ATC) classification system designating it as C05BX01 under “Other sclerosing agents”. This classification reflects its primary therapeutic applications in vascular disorders. As of 2025, calcium dobesilate continues to maintain a stable regulatory presence globally, with ongoing clinical research potentially expanding its approved indications in various territories.
The compound’s long-established safety profile and decades of clinical use have contributed to its favorable standing with regulatory authorities worldwide, making it a reliable option for healthcare providers treating various vascular conditions.
Conclusion
Calcium dobesilate monohydrate represents an important therapeutic agent in the management of various vascular disorders, particularly those involving microcirculation impairment and increased capillary permeability.
Its multifaceted mechanism of action-reducing capillary leakage, improving blood rheology, enhancing nitric oxide production, and demonstrating anti-inflammatory properties-provides a comprehensive approach to addressing the complex pathophysiology of conditions such as diabetic retinopathy, chronic venous insufficiency, and hemorrhoidal disease.
The extensive clinical experience with calcium dobesilate spanning several decades has established a favorable safety profile characterized by low incidence of adverse effects and minimal drug interactions. This safety profile, combined with its demonstrated efficacy across multiple clinical indications, has contributed to its widespread use in more than 60 countries worldwide.
As research continues to explore additional applications and refine our understanding of its mechanisms, calcium dobesilate monohydrate is likely to remain an important component of vascular disease management strategies.
Healthcare providers should consider calcium dobesilate as a valuable option in their therapeutic armamentarium, particularly for patients with microvascular complications of diabetes, chronic venous disorders, and other conditions involving vascular dysfunction.
Future research directions may include exploring its potential benefits in additional indications, optimizing dosing regimens, and developing novel formulations to enhance its therapeutic efficacy while maintaining its excellent safety profile.
